FDA Approves New Ablation Catheter to Treat Atrial Fibrillation

Article

The US Food and Drug Administration (FDA) has approved a new ablation catheter for use in patients with medication-resistant paroxysmal atrial fibrillation.

The US Food and Drug Administration (FDA) has approved a new ablation catheter for use in patients with medication-resistant paroxysmal atrial fibrillation (AF), type 1 atrial flutter, and sustained monomorphic ischemic ventricular tachycardia.

The Thermocool Smarttouch is the first therapeutic catheter approved to enable direct and real-time measurement of contact force during ablation procedures, which allows stable application of contact force, according to the device’s manufacturer, Biosense Webster.

Data from the SMART-AF trial presented at the Heart Rhythm Society’s meeting in May 2013 showed the catheter had a 74% overall success rate in drug-resistant AF patients. The device’s success rates were even higher when physicians stayed within a targeted contact force range for long time periods, as 1-year results demonstrated 88% success rates when physicians were within contact force range ≥85% of the time.

The catheter provides contact force stability while physicians apply radiofrequency energy against the heart wall during catheter ablation. Without the technology, catheter tip-to-tissue contact must be estimated through indirect methods that are poor predictors of contact force, the manufacturer noted.

The SMART-AF trial deemed the catheter safe in AF patients, with an adverse event rate of 9.9% at 7 days.

Recent Videos
Brendon Neuen, MBBS, PhD | Credit: X.com
A panel of 5 cardiovascular experts
Video 5 - "Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice" - Featuring 1 KOL
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Video 4 - "Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes "
Video 3 - "Aligning With 2023 ESC Guidelines in oHCM Treatment"
Robert Rosenson, MD | Credit: Cura Foundation
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
© 2024 MJH Life Sciences

All rights reserved.